Register Login

Talaris Therapeutics Inc (TALS)

  • Event
  • May 12, 2022, 20:07 UTC

(10% Negative) TALARIS THERAPEUTICS, INC. (TALS) Announces Delay in results Trials for our pipeline programs Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 1, 2025, 3:42 p.m.

    📋 TALARIS THERAPEUTICS, INC. (TALS) - Clinical Trial Update

    Filing Date: 2022-05-12

    Accepted: 2022-05-12 16:07:46

    Event Type: Clinical Trial Update

    Event Details:

    Talaris Therapeutics Inc (TALS) Announces Clinical Trial Update Talaris Therapeutics Inc (TALS) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: results, recipients
    • Diseases/Conditions: our pipeline programs
    • Clinical Stage: Phase 3, clinical study
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
    • Collaboration: Talaris Therapeutics, Inc.

    💼 Business Developments:

    No business developments data available.

    Structured Data:

    • Company Name: Talaris Therapeutics Inc
    • CIK: 0001827506
    • Ticker Symbol: TALS
    • Period End Date: 2022-05-12
    • Document Type: 8-K

Search

News categories